StreetInsider.com News Articles

Form 8-K Cocrystal Pharma, Inc. For: Mar 09

Mon, 09 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260309/26129421.html

Form 8-K Cocrystal Pharma, Inc. For: Mar 09

Mon, 09 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260309/26129421.html

Cocrystal Pharma begins dosing first subjects in norovirus drug trial

Mon, 09 Mar 2026 08:00:10 -0400

Cocrystal Pharma Inc. (NASDAQ: COCP) has started dosing the first subjects in a Phase 1b clinical study evaluating CDI-988 for norovirus prevention and treatment. The randomized, double-blind, placebo-controlled study is being conducted at Emory University School of Medicine.

The study will enroll up to 40 healthy subjects ages 18-49, all of whom will be infected with the norovirus GII.2 strain. The first cohort aims to assess the infectivity rate of the challenge inoculum, while subsequent cohorts will receive either CDI-988 or placebo.

CDI-988 is described as a direct-acting, oral antiviral designed to inhibit the viral 3CL protease present in all known norovirus

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Mon, 09 Mar 2026 08:00:00 -0400

CDI-988 is a direct-acting, oral antiviral being developed for norovirus
Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988
No approved treatments or vaccines are available for norovirus treatment and prevention, posing a significant unmet need and contributing to a global economic burden of $60 billion annually

BOTHELL, Wash., March 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the first subjects have been dosed in a Phase 1b norovirus challenge study (NCT07198139)

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Mon, 09 Mar 2026 08:00:00 -0400

CDI-988 is a direct-acting, oral antiviral being developed for norovirus
Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988
No approved treatments or vaccines are available for norovirus treatment and prevention, posing a significant unmet need and contributing to a global economic burden of $60 billion annually

Form 4 Cocrystal Pharma, Inc. For: Feb 24 Filed by: FROST PHILLIP MD ET AL

Wed, 25 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260225/26059984.html

Form 4 Cocrystal Pharma, Inc. For: Feb 24 Filed by: FROST PHILLIP MD ET AL

Wed, 25 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260225/26059984.html

Form 8-K Cocrystal Pharma, Inc. For: Feb 19

Thu, 19 Feb 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260219/26026647.html

Form 8-K Cocrystal Pharma, Inc. For: Feb 19

Thu, 19 Feb 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260219/26026647.html

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Thu, 19 Feb 2026 08:00:00 -0400

CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections
Company to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of Medicine
No approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need

BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its direct-acting, oral protease inhibitor CDI-988 will be presented at the 39^th

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Thu, 19 Feb 2026 08:00:00 -0400

CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections
Company to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of Medicine
No approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need

Form 4 Cocrystal Pharma, Inc. For: Feb 06 Filed by: FROST PHILLIP MD ET AL

Mon, 09 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260209/25968152.html

Form 4 Cocrystal Pharma, Inc. For: Feb 06 Filed by: FROST PHILLIP MD ET AL

Mon, 09 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260209/25968152.html

Form 8-K Cocrystal Pharma, Inc. For: Jan 09

Thu, 15 Jan 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260115/25855687.html

Form 8-K Cocrystal Pharma, Inc. For: Jan 09

Thu, 15 Jan 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260115/25855687.html

Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Kornberg Roger D.

Tue, 13 Jan 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260113/25844849.html

Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Kornberg Roger D.

Tue, 13 Jan 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260113/25844849.html

Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: FROST PHILLIP MD ET AL